Physician profile
Michael Patrick Whitledge
NPI 1174852149
$12,170.95
in general payments reported to CMS, 2019-2025
52 companies · $2,265 in 2025
The $2,265 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,694 · 2022: $2,557 · 2023: $2,612 · 2024: $2,042 · 2025: $2,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,919.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,628.35 | 2021-2025 | |
| Novo Nordisk INC | $1,353.18 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,088.58 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $1,081.45 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Axsome Therapeutics, INC. | $659.89 | 2023-2025 | Auvelity, Sunosi |
| Glaxosmithkline, LLC. | $557.24 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $383.95 | 2021-2025 | Spravato, Invega Sustenna |
| Bayer Healthcare Pharmaceuticals INC. | $374.02 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $361.92 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Otsuka America Pharmaceutical, INC. | $354.79 | 2021-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $354.50 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $328.37 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $287.95 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $276.59 | 2021-2025 | Otezla, Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $275.64 | 2021-2023 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $222.42 | 2021-2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Novartis Pharmaceuticals Corporation | $206.21 | 2021-2025 | |
| Exact Sciences Corporation | $182.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $180.45 | 2021-2025 | Austedo Xr, Austedo Xr, Airduo Digihaler |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $171.86 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $138.91 | 2021-2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $126.11 | 2023-2025 | Quviviq, Quviviq |
| Kowa Pharmaceuticals America, INC. | $122.15 | 2021-2023 | Seglentis, Livalo |
| Amarin Pharma, INC. | $99.15 | 2021-2022 | |
| Lundbeck LLC | $94.15 | 2022-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $92.60 | 2022 | |
| Jazz Pharmaceuticals INC. | $92.21 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $91.91 | 2021 | |
| Harmony Biosciences LLC | $86.84 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.26 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $68.60 | 2024-2025 | Voquezna |
| Eisai INC. | $68.28 | 2021-2022 | |
| Insulet Corporation | $67.80 | 2021-2025 | Omnipod |
| Corium, LLC | $62.49 | 2022-2025 | Azstarys |
| Corcept Therapeutics | $55.67 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $54.36 | 2021-2025 | Nexletol |
| Clarus Therapeutics INC. | $51.57 | 2021 | |
| Abbott Laboratories | $37.88 | 2025 | Freestyle Libre 3 |
| Hikma Pharmaceuticals USA | $36.70 | 2021 | |
| Eyevance Pharmaceuticals LLC | $36.70 | 2021 | |
| Supernus Pharmaceuticals, INC. | $34.74 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $32.84 | 2021 | |
| Boston Scientific Corporation | $32.28 | 2023 | |
| Vanda Pharmaceuticals INC. | $27.18 | 2025 | Fanapt |
| Scilex Pharmaceuticals INC. | $24.27 | 2024 | |
| Antares Pharma, INC. | $21.65 | 2022 | |
| Daiichi Sankyo INC. | $19.93 | 2021 | |
| Alkermes, INC. | $19.16 | 2023 | Aristada, Lybalvi |
| Adlon Therapeutics L.P. | $17.82 | 2021 | |
| Ironwood Pharmaceuticals, INC | $16.31 | 2024 | |
| Currax Pharmaceuticals LLC | $16.23 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $14.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Whitledge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.